Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

Data to be presented at ASCO in June suggests Pfizer’s Ibrance has a good shot at maintaining a leadership position in the category as competitors Lilly and Novartis step closer to the market.

Advertisement

Related Content

Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Korea Green Light For Pfizer’s Novel Breast Cancer Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel